x
BioICAWTech

  • Helsinki, Finland
  • 666-888-0000
  • info@bioicawtech.com
BioICAWTech
  • info@bioicawtech.com
  • Helsinki, Finland
  • Request a quote
  • Home
  • About us
  • Services
    • Data scraping
    • Chemoinformatics analysis
    • Precision medicine
    • Sequencing analysis
  • Portfolio
    • Drug repurposing
    • Repurpose Drug catalogue
    • Pharamocofiler
    • AI based prediction of adverse drug reactions
    • Identification of synergistic drug combinations
    • AI based drug-response prediction using multi-omics
  • Publication
  • Team
  • Contact us
Logo

AI based prediction of adverse drug reactions

    BioICAWTech > AI based prediction of adverse drug reactions

AI based prediction of adverse drug reactions

The post-marketing reports of adverse events for approved drugs and their combinations are available in VigiBase, FAERS, VAERS and JADER databases. However, some approved drugs and combinations are still missing there. Therefore, we have started developing an AI-based models to predict adverse events for the missing drugs and combinations in this project.

Figure: AI based prediction models for adverse events. Models are trained based on two sets of descriptors: 1) drug induced gene expression profiles available at L1000 (level5) dataset averaged across each cell line and different time points (columns= genes, rows= drugs), and 2) ECFP4 structural fingerprints for drugs. Labels are 2078 adverse events present in SIDER database. A) Adverse event prediction model for single drugs, B) drug combinations

AI models are trained based on the drug’s structural fingerprints (ECFP4) and transcriptomic profiles from the LINCS L1000 database (https://lincsproject.org/LINCS/). For the sake of simplicity, we take an average of gene expression values across all cell lines and time points, resulting in a 12,328 x 3492 matrix (12,328 genes and 3492 drugs). ECFP4 has a bit string of length 2048.

We combine both vectors so that each drug will be represented by a descriptor vector of length 14376 (12,328+ 2048). For the drug combination model, the length of the descriptor vector is doubled. Integrating transcriptomic data from the LINCS L1000 dataset with chemical structural fingerprints enabled us to capture molecular and structural information, providing a more comprehensive representation of the compounds for adverse events prediction. Following figure shows the workflow of our proposed method.

A Finland-based IT company specializing in delivering tailored software solutions and development services for healthcare providers and medical businesses.

  • Helsinki, Finland
  • info@bioicawtech.com

Articles

  • MICHA
  • 2023 FDA approvals
  • Efficacy vs Potency

Useful Links

  • About Us
  • Blogs
  • Contact Us

BioIcawTech © 2023 All Right Reserved